Stem cell banking contract service provider, Human Biostar and RNL Bio have revised and supplemented Human Biostar's stem cell laboratory (GTP Centre I) in compliance with US FDA regulation.
Subscribe to our email newsletter
The lab, which was temporarily shut down for revision, has again resumed operations to serve stem cell banking customers.
The GTP Centre I, which has been initially completed on 11 October 2011, has a processing capacity of up to 3,000 customers per annum.
Recently Human Biostar has also organised an open lab event to explain revisions made in its GTP Centre I’s configuration and operation system according to FDA recommendations.
South Korea-based RL Bio contributes to human health with stem cell research and development in collaboration with the global medical and scientific institutions.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.